Bulletin from Annual General Meeting of Diamyd Medical AB
The following items were addressed at the Annual General Meeting of Diamyd Medical AB (publ) held today:
Diamyd Medical's President and CEO Peter Zerhouni gave a retrospective view of the past year and summarized the most significant events that took place during the fiscal year and after year-end.
The Company's income statement and balance sheet were adopted and the Board members and the Chief Executive Officer were discharged from liability for the 2012/2013 fiscal year. The Annual General Meeting approved the Board's proposal that no dividend be paid for the 2012/2013 fiscal year.
Anders Essen-Möller was re-elected as Chairman of the Board and Maria-Teresa Essen-Möller and Erik Nerpin were re-elected to the Board.
The Annual General Meeting approved the proposed remuneration to Board members and the Chairman of the Board.
The Annual General Meeting resolved to re-elect the auditing company PricewaterhouseCoopers AB until the end of the Annual General Meeting 2014. Principal auditor is the authorized public accountant Eva Blom.
The AGM resolved to authorize the Board, on one or more occasions prior to the next Annual General Meeting to issue shares and to deviate from the shareholders' preferential rights when so doing. Payment may be made in cash, through a contribution or by offsetting. In a share issue for cash payment and in deviation from the shareholders' preferential rights, the number of shares issued pursuant to the authorization may not exceed 20 percent of the shares in the Company when the share issue occurs.
For further information, please contact:
Peter Zerhouni, President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26. E-mail: press@diamyd.com
About Diamyd Medical
Diamyd Medical is a Swedish diabetes company. The Company’s primary development project consists of the GAD-based diabetes vaccine Diamyd®for the treatment and prevention of autoimmune diabetes. Two Swedish researcher-initiated Phase II studies with Diamyd®are ongoing. One study evaluates whether the diabetes vaccine can prevent type 1 diabetes in children who are at high risk of developing the disease, while the other study evaluates whether Diamyd®in combination with relatively high doses of vitamin D and ibuprofen can preserve the body's own ability to regulate the blood sugar level in children and adolescents newly diagnosed with type 1 diabetes.
In May 2013 the Company concluded an exclusive licensing agreement with the University of California in Los Angeles (UCLA) relating to a patent portfolio for the therapeutic use of GABA (gamma-aminobutyric acid) and GABA receptor agonists for the treatment and prevention of type 1 and type 2 diabetes and other inflammation-related conditions, such as metabolic syndrome, rheumatoid arthritis and allergies.
Diamyd Medical also has holdings in the gene therapy company Periphagen Holdings, Inc. (US).
Diamyd Medical’s Series B share is traded on NASDAQ OMX First North under the ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser. Further information is available on the Company’s website: www.diamyd.com.
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797.
Tags: